Economic and Environmental Initiatives for Inhaled Products

The podium presentations and discussion were recorded on April 27 at Respiratory Drug Delivery 2010 in Orlando, Florida to provide a broad perspective on 'Economic and Environmental Initiatives for Inhaled Products'.

This session provides an overview of the current status of the phase-out of CFC MDIs followed by presentations highlighting the scientific, regulatory, political and commercial challenges that are associated with inhaler development in Article 5 countries including China and India. A lively panel discussion chaired by Professor Ashley Woodcock followed.

This presentation consists of a series of audio lectures and synchronized powerpoint slides. It is possible to watch all, or only segments of, the presentation as time permits. The duration of the full presentation is approximately 2 hours and has been made possible by the generous support of 3M Drug Delivery Systems.

Complimentary copies of advocacy articles for each of the individual discussions are available online and as an attachment within each presentation. Articles are also included in Respiratory Drug Delivery 2010 Proceedings.

Responsible Inhaler Development in Article V Countries: Navigating the Scientific, Regulatory, Political and Commercial Challenges.

Ashley Woodcock, M.D.
University of Manchester, Manchester, United Kingdom.

Inhaler Development in Developing Markets: Overcoming Barriers to Successful Implementation.

David J. Howlett, B.A.
PharmaDelivery Solutions, Grimston, United Kingdom.

Status, Challenges and Regulatory Strategies for Propellant Replacement in China.

Shuguang Hou, Ph.D.
3M Drug Delivery Systems, St. Paul, MN.

Inhalers for the Indian Subcontinent: Environmental and Therapeutic Imperatives.

Raj B. Singh, M.D.
Apollo Hospital, Chennai, India.

Respiratory Drug Delivery 2010 Panel Discussion

Chairperson

Ashley Woodcock, M.D.,
University of Manchester, Manchester, United Kingdom.

Panel

  • Badrul A. Chowdhury, M.D. Ph.D.,
    Food and Drug Administration, Silver Springs, MD.
  • Shuguang Hou, Ph.D.,
    3M Drug Delivery Systems, St Paul, MN.
  • David J. Howlett, B.A.,
    PharmaDelivery Solutions, Grimston, United Kingdom.
  • Fang Jin, Ph.D.,
    Shanghai Institute of Pharmaceutical Industry, Shanghai, China.
  • Raj. B. Singh, M.D.,
    Apollo Hospital, Chennai, India.

During the Panel Discussion at Respiratory Drug Delivery 2010, Peter Byron (VCU), Nelson Lago (Laboratorios Haymann), Mike Newhouse (McMaster University), John Pritchard (AstraZeneca), Charlie Thiel (Retired), Geraldine Venthoye (SkyePharma), and Patrick Yelverton (GlaxoSmithKline) agreed to the inclusion of their questions and comments.

The RDD Online editorial team has added slides which summarize the issues discussed during the Q&A session with the audience.